Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Series TitleSeries Title
-
Reading LevelReading Level
-
YearFrom:-To:
-
More FiltersMore FiltersContent TypeItem TypeIs Full-Text AvailableSubjectCountry Of PublicationPublisherSourceTarget AudienceDonorLanguagePlace of PublicationContributorsLocation
Done
Filters
Reset
1,323,731
result(s) for
"Aged"
Sort by:
Correction: Impact of hearing impairment on the mental status of the adults and older adults in Jordanian society
2024
[This corrects the article DOI: 10.1371/journal.pone.0298616.].
Journal Article
Correction: Normative reference values of handgrip strength for Brazilian older people aged 65 to 90 years: Evidence from the multicenter Fibra‑BR study
[This corrects the article DOI: 10.1371/journal.pone.0250925.].
Journal Article
Fitness after 40 : your strong body at 40, 50, 60, and beyond
\"Includes a 6-week total-body workout program.\"
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
2015
In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with progression-free survival of more than 9 months, as compared with less than 4 months with fulvestrant alone.
Approximately 80% of breast cancers express estrogen receptors, progesterone receptors, or both. Endocrine therapies are the mainstay of treatment for these hormone-receptor–positive cancers, substantially reducing the relapse rate after presentation with early-stage cancer.
1
Despite advances in endocrine therapy, many women have a relapse during or after completing adjuvant therapy. The care of these women remains a considerable clinical challenge. Single-agent treatment with an aromatase inhibitor or tamoxifen has shown limited clinical benefit.
2
,
3
The selective estrogen-receptor degrader fulvestrant has modest activity in this population of patients,
4
,
5
and the development of effective therapies that can reverse resistance to endocrine therapy . . .
Journal Article
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
by
Van Cutsem, Eric
,
Mizuguchi, Hirokazu
,
Peeters, Marc
in
Adenocarcinoma - drug therapy
,
Adenocarcinoma - mortality
,
Adenocarcinoma - secondary
2015
TAS-102, a combination of trifluridine and tipiracil in which tipiracil interferes with the deactivation of trifluridine, improved overall and progression-free survival in patients whose disease had progressed after treatment with fluorouracil-containing drug combinations.
Fluoropyrimidines have long represented the cornerstone of treatment for colorectal cancer.
1
Such compounds act primarily as inhibitors of thymidylate synthase, the rate-limiting enzyme in the synthesis of pyrimidine nucleotides.
2
Fluorouracil has been combined with folinic acid (also known as leucovorin) to enhance the capacity of fluorouracil to bind to thymidylate synthase.
2
The addition of irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) to fluorouracil and folinic acid, in combination with either a vascular endothelial growth factor inhibitor (bevacizumab) or an epidermal growth factor inhibitor (e.g., cetuximab or panitumumab) if the tumor contains a wild-type
RAS
gene, represents contemporary standard therapy and has extended . . .
Journal Article
How can my husband and I best care for our elderly parents?
2025
Washington Post advice columnist Carolyn Hax offers a key suggestion to a reader caring for her elderly parents and in-laws.
Streaming Video